Abstract
Radiotherapy can boost the therapeutic response to immune checkpoint inhibitors (ICIs) by recruiting T lymphocytes and upregulating PD-L1 expression within the tumor microenvironment (TME). Our previous studies found that tumor PD-L1 expression cannot be induced in some locally advanced colorectal cancer (CRC) patients who receive preoperative concurrent chemoradiotherapy (CCRT) even in the presence of abundant T lymphocytes. We aimed to evaluate whether PD-L1 promoter methylation impacted the response to CCRT and acted as an independent biomarker for locally advanced CRC patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
